Symbols / BLRX $2.25 -5.06% BioLineRx Ltd.
BLRX Chart
About
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 10.12M |
| Enterprise Value | 5.87B | Income | -1.18M | Sales | 1.18M |
| Book/sh | 0.01 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | inf | Forward P/E | -3.36 | PEG | — |
| P/S | 8.58 | P/B | 321.43 | P/C | — |
| EV/EBITDA | -583.38 | EV/Sales | 4973.52 | Quick Ratio | 1.76 |
| Current Ratio | 1.95 | Debt/Eq | 43.48 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | -0.67 | EPS Growth | — |
| Revenue Growth | -98.30% | Earnings | 2026-05-27 | ROA | -16.11% |
| ROE | -11.01% | ROIC | — | Gross Margin | 80.51% |
| Oper. Margin | -17.45% | Profit Margin | -99.58% | Shs Outstand | 4.35M |
| Shs Float | 2.50B | Short Float | 3.86% | Short Ratio | 16.96 |
| Short Interest | — | 52W High | 7.77 | 52W Low | 2.25 |
| Beta | 0.46 | Avg Volume | 14.86K | Volume | 16.26K |
| Target Price | $20.33 | Recom | Strong_buy | Prev Close | $2.37 |
| Price | $2.25 | Change | -5.06% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-05-30 | up | Jones Trading | Hold → Buy | $12 |
| 2025-05-28 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-04-02 | down | Jones Trading | Buy → Hold | — |
| 2025-03-31 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-11-25 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-11-06 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-04-17 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-02-29 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-09-15 | main | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-08-31 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2023-05-25 | reit | Oppenheimer | — → Outperform | $4 |
| 2021-02-23 | main | HC Wainwright & Co. | — → Buy | $19 |
| 2020-12-16 | main | HC Wainwright & Co. | — → Buy | $22 |
| 2017-08-04 | init | Oppenheimer | — → Outperform | $3 |
| 2017-05-18 | up | Maxim Group | Hold → Buy | — |
- BioLineRx (BLRX) director discloses 2,055,000 option-linked shares - Stock Titan Mon, 30 Mar 2026 22
- [Form 3] BioLineRx Ltd. Initial Statement of Beneficial Ownership - Stock Titan Mon, 30 Mar 2026 21
- H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025 - Yahoo Finance Wed, 02 Jul 2025 07
- BLRX PE Ratio & Valuation, Is BLRX Overvalued - Intellectia AI Sun, 29 Mar 2026 18
- Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings - Benzinga Fri, 20 Mar 2026 06
- BLRX Beats Earnings, Misses Revenue as Stock Dives - Bitget Mon, 23 Mar 2026 12
- BioLineRx to Report 2025 Annual Results on March 23, 2026 - Finviz Mon, 23 Mar 2026 07
- 3 Stocks Getting Rare Double Upgrades From Analysts - marketbeat.com Fri, 06 Jun 2025 07
- JonesTrading Maintains BioLine Rx(BLRX.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛 Sat, 28 Mar 2026 12
- BioLineRx (NASDAQ: BLRX) CEO details 5.1M shares and multiple option grants - Stock Titan Fri, 27 Mar 2026 20
- BIOLINE RX LTD SET TO LAUNCH PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA TREATMENT BY MONTH'S END - Intellectia AI Fri, 27 Mar 2026 18
- New oral brain cancer drug enters human testing, data due in 2027 - Stock Titan hu, 26 Mar 2026 11
- BioLineRx (NASDAQ: BLRX) files Form 20-F/A to correct auditor consent - Stock Titan Fri, 27 Mar 2026 20
- BioLineRx says its brain cancer drug enters human testing this month - Stock Titan Mon, 23 Mar 2026 11
- [6-K] BioLineRx Ltd. Current Report (Foreign Issuer) | BLRX SEC Filing - Form 6-K - Stock Titan hu, 26 Mar 2026 11
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
28.94
+502.92%
|
4.80
|
0.00
|
0.00
|
| Operating Revenue |
|
28.94
+502.92%
|
4.80
|
0.00
|
0.00
|
| Cost Of Revenue |
|
9.26
+150.89%
|
3.69
|
0.00
|
0.00
|
| Reconciled Cost Of Revenue |
|
5.54
+108.27%
|
2.66
|
0.00
|
0.00
|
| Gross Profit |
|
19.68
+1675.90%
|
1.11
|
0.00
|
0.00
|
| Operating Expense |
|
38.83
-11.95%
|
44.10
+51.25%
|
29.16
+17.68%
|
24.78
|
| Research And Development |
|
9.15
-26.92%
|
12.52
-28.99%
|
17.63
-9.44%
|
19.47
|
| Selling General And Administration |
|
28.54
-8.61%
|
31.23
+171.82%
|
11.49
+118.05%
|
5.27
|
| Selling And Marketing Expense |
|
10.08
-30.92%
|
14.59
+198.89%
|
4.88
+547.48%
|
0.75
|
| General And Administrative Expense |
|
18.46
+10.96%
|
16.64
+151.81%
|
6.61
+46.33%
|
4.51
|
| Salaries And Wages |
|
14.91
+19.10%
|
12.52
+241.97%
|
3.66
+63.39%
|
2.24
|
| Other Gand A |
|
2.75
-13.73%
|
3.18
+67.39%
|
1.90
+56.98%
|
1.21
|
| Total Expenses |
|
48.09
+0.63%
|
47.79
+63.91%
|
29.16
+17.68%
|
24.78
|
| Operating Income |
|
-19.15
+55.45%
|
-42.99
-47.45%
|
-29.16
-17.68%
|
-24.78
|
| Total Operating Income As Reported |
|
-20.41
+58.93%
|
-49.69
-70.44%
|
-29.16
-17.68%
|
-24.78
|
| EBITDA |
|
3.92
+106.86%
|
-57.09
-153.59%
|
-22.51
+11.26%
|
-25.37
|
| Normalized EBITDA |
|
-13.84
+64.86%
|
-39.39
-37.78%
|
-28.59
-20.57%
|
-23.71
|
| Reconciled Depreciation |
|
4.07
+193.71%
|
1.38
+111.62%
|
0.65
-6.97%
|
0.70
|
| EBIT |
|
-0.15
+99.75%
|
-58.47
-152.41%
|
-23.16
+11.14%
|
-26.07
|
| Total Unusual Items |
|
17.76
+200.36%
|
-17.70
-391.10%
|
6.08
+467.53%
|
-1.65
|
| Total Unusual Items Excluding Goodwill |
|
17.76
+200.36%
|
-17.70
-391.10%
|
6.08
+467.53%
|
-1.65
|
| Special Income Charges |
|
-1.26
+81.26%
|
-6.70
|
0.00
|
0.00
|
| Other Special Charges |
|
0.25
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
1.01
-84.93%
|
6.70
|
0.00
|
0.00
|
| Net Income |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Pretax Income |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Net Non Operating Interest Income Expense |
|
-7.30
-4405.56%
|
-0.16
+85.51%
|
-1.12
-53.36%
|
-0.73
|
| Interest Expense Non Operating |
|
9.07
+323.23%
|
2.14
+20.04%
|
1.79
+81.50%
|
0.98
|
| Net Interest Income |
|
-7.30
-4405.56%
|
-0.16
+85.51%
|
-1.12
-53.36%
|
-0.73
|
| Interest Expense |
|
9.07
+323.23%
|
2.14
+20.04%
|
1.79
+81.50%
|
0.98
|
| Interest Income Non Operating |
|
1.82
-9.32%
|
2.01
+189.19%
|
0.69
+150.54%
|
0.28
|
| Interest Income |
|
1.82
-9.32%
|
2.01
+189.19%
|
0.69
+150.54%
|
0.28
|
| Other Income Expense |
|
17.23
+198.68%
|
-17.46
-427.97%
|
5.32
+443.93%
|
-1.55
|
| Other Non Operating Income Expenses |
|
-0.53
-325.53%
|
0.23
+131.13%
|
-0.76
-812.26%
|
0.11
|
| Gain On Sale Of Security |
|
19.02
+272.98%
|
-10.99
-280.84%
|
6.08
+467.53%
|
-1.65
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Net Income From Continuing Operation Net Minority Interest |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Net Income From Continuing And Discontinued Operation |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Net Income Continuous Operations |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Normalized Income |
|
-26.98
+37.13%
|
-42.92
-38.31%
|
-31.03
-22.17%
|
-25.40
|
| Net Income Common Stockholders |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Diluted EPS |
|
-6.00
+83.33%
|
-36.00
-100.00%
|
-18.00
+25.00%
|
-24.00
|
| Basic EPS |
|
-6.00
+83.33%
|
-36.00
-100.00%
|
-18.00
+25.00%
|
-24.00
|
| Basic Average Shares |
|
2.00
+24.37%
|
1.61
+24.47%
|
1.29
+16.75%
|
1.10
|
| Diluted Average Shares |
|
2.00
+24.37%
|
1.61
+24.47%
|
1.29
+16.75%
|
1.10
|
| Diluted NI Availto Com Stockholders |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Depreciation Amortization Depletion Income Statement |
|
0.34
-3.13%
|
0.35
+800.00%
|
0.04
-7.14%
|
0.04
|
| Depreciation And Amortization In Income Statement |
|
0.34
-3.13%
|
0.35
+800.00%
|
0.04
-7.14%
|
0.04
|
| Depreciation Income Statement |
|
0.34
-3.13%
|
0.35
+800.00%
|
0.04
-7.14%
|
0.04
|
| Insurance And Claims |
|
0.81
-13.95%
|
0.94
-10.23%
|
1.05
-1.69%
|
1.06
|
| Provision For Doubtful Accounts |
|
0.80
|
0.00
|
0.00
|
—
|
| Total Other Finance Cost |
|
0.04
+80.00%
|
0.03
-3.85%
|
0.03
+18.18%
|
0.02
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
38.91
-39.14%
|
63.92
-16.31%
|
76.38
-6.15%
|
81.39
|
| Current Assets |
|
27.10
-42.56%
|
47.18
-9.27%
|
52.00
-9.41%
|
57.40
|
| Cash Cash Equivalents And Short Term Investments |
|
19.56
-54.50%
|
42.99
-15.83%
|
51.08
-10.59%
|
57.13
|
| Cash And Cash Equivalents |
|
10.44
+145.26%
|
4.25
-59.81%
|
10.59
-18.50%
|
12.99
|
| Cash Equivalents |
|
9.49
+762.13%
|
1.10
-84.19%
|
6.96
+53.76%
|
4.53
|
| Cash Financial |
|
0.94
-70.07%
|
3.15
-12.95%
|
3.62
-57.18%
|
8.46
|
| Other Short Term Investments |
|
9.13
-76.44%
|
38.74
-4.34%
|
40.49
-8.27%
|
44.15
|
| Receivables |
|
3.86
+445.62%
|
0.71
-1.80%
|
0.72
+407.75%
|
0.14
|
| Accounts Receivable |
|
2.48
+591.62%
|
0.36
|
0.00
|
—
|
| Other Receivables |
|
1.39
+296.29%
|
0.35
-51.46%
|
0.72
+407.75%
|
0.14
|
| Inventory |
|
3.15
+61.03%
|
1.95
|
0.00
|
—
|
| Raw Materials |
|
0.00
-100.00%
|
0.90
|
0.00
|
—
|
| Work In Process |
|
2.98
+532.70%
|
0.47
|
0.00
|
—
|
| Finished Goods |
|
0.17
-71.50%
|
0.58
|
0.00
|
—
|
| Prepaid Assets |
|
0.53
-65.05%
|
1.53
+671.72%
|
0.20
+55.91%
|
0.13
|
| Total Non Current Assets |
|
11.80
-29.51%
|
16.74
-31.34%
|
24.38
+1.65%
|
23.99
|
| Net PPE |
|
1.35
-28.34%
|
1.89
-24.42%
|
2.50
+9.42%
|
2.28
|
| Gross PPE |
|
6.33
-14.75%
|
7.43
+2.03%
|
7.28
+6.76%
|
6.82
|
| Accumulated Depreciation |
|
-4.98
+10.13%
|
-5.54
-15.85%
|
-4.78
-5.42%
|
-4.54
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.17
-30.20%
|
1.68
+9.15%
|
1.54
-6.55%
|
1.65
|
| Other Properties |
|
1.57
-2.60%
|
1.61
+0.44%
|
1.61
+1.01%
|
1.59
|
| Leases |
|
3.59
-13.21%
|
4.13
+0.00%
|
4.13
+15.45%
|
3.58
|
| Goodwill And Other Intangible Assets |
|
10.45
-29.66%
|
14.85
-32.13%
|
21.89
+0.83%
|
21.70
|
| Other Intangible Assets |
|
10.45
-29.66%
|
14.85
-32.13%
|
21.89
+0.83%
|
21.70
|
| Total Liabilities Net Minority Interest |
|
25.45
-49.81%
|
50.70
+98.50%
|
25.54
+91.99%
|
13.30
|
| Current Liabilities |
|
15.41
-63.99%
|
42.78
+300.64%
|
10.68
+9.88%
|
9.72
|
| Payables And Accrued Expenses |
|
8.28
-39.99%
|
13.80
+65.64%
|
8.33
+30.26%
|
6.40
|
| Payables |
|
5.58
-49.05%
|
10.96
+55.42%
|
7.05
+26.59%
|
5.57
|
| Accounts Payable |
|
5.58
-48.63%
|
10.87
+56.03%
|
6.97
+25.13%
|
5.57
|
| Other Payable |
|
—
|
0.09
+4.76%
|
0.08
+4100.00%
|
0.00
|
| Current Accrued Expenses |
|
2.70
-5.13%
|
2.85
+121.82%
|
1.28
+54.95%
|
0.83
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.43
+2.86%
|
0.42
+11.14%
|
0.38
-5.04%
|
0.40
|
| Current Debt And Capital Lease Obligation |
|
5.00
+36.16%
|
3.67
+86.54%
|
1.97
-32.68%
|
2.92
|
| Current Debt |
|
4.48
+42.42%
|
3.15
+103.96%
|
1.54
-44.07%
|
2.76
|
| Other Current Borrowings |
|
4.48
+42.42%
|
3.15
+103.96%
|
1.54
-44.07%
|
2.76
|
| Current Capital Lease Obligation |
|
0.52
-1.14%
|
0.53
+23.65%
|
0.43
+154.17%
|
0.17
|
| Current Deferred Liabilities |
|
0.00
-100.00%
|
12.96
|
0.00
|
—
|
| Current Deferred Revenue |
|
0.00
-100.00%
|
12.96
|
0.00
|
—
|
| Other Current Liabilities |
|
1.69
-85.83%
|
11.93
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
10.04
+26.79%
|
7.92
-46.73%
|
14.86
+314.62%
|
3.58
|
| Long Term Debt And Capital Lease Obligation |
|
10.04
+26.79%
|
7.92
-23.53%
|
10.36
+499.94%
|
1.73
|
| Long Term Debt |
|
8.96
+35.15%
|
6.63
-23.16%
|
8.63
|
—
|
| Long Term Capital Lease Obligation |
|
1.08
-16.20%
|
1.29
-25.39%
|
1.73
+0.17%
|
1.73
|
| Stockholders Equity |
|
13.46
+1.80%
|
13.22
-73.99%
|
50.84
-25.33%
|
68.09
|
| Common Stock Equity |
|
13.46
+1.80%
|
13.22
-73.99%
|
50.84
-25.33%
|
68.09
|
| Capital Stock |
|
38.10
+21.50%
|
31.36
+15.70%
|
27.10
+28.64%
|
21.07
|
| Common Stock |
|
38.10
+21.50%
|
31.36
+15.70%
|
27.10
+28.64%
|
21.07
|
| Share Issued |
|
1,336.67
+23.02%
|
1,086.59
+17.73%
|
922.96
+29.06%
|
715.16
|
| Ordinary Shares Number |
|
1,336.67
+23.02%
|
1,086.59
+17.73%
|
922.96
+29.06%
|
715.16
|
| Additional Paid In Capital |
|
353.69
-0.50%
|
355.48
+4.87%
|
338.98
-0.11%
|
339.35
|
| Retained Earnings |
|
-399.83
-2.36%
|
-390.61
-18.37%
|
-329.99
-8.18%
|
-305.04
|
| Gains Losses Not Affecting Retained Earnings |
|
16.13
+3.51%
|
15.58
+16.74%
|
13.35
+13.70%
|
11.74
|
| Other Equity Adjustments |
|
16.13
+3.51%
|
15.58
+16.74%
|
13.35
+13.70%
|
11.74
|
| Total Equity Gross Minority Interest |
|
13.46
+1.80%
|
13.22
-73.99%
|
50.84
-25.33%
|
68.09
|
| Total Capitalization |
|
22.42
+12.94%
|
19.85
-66.62%
|
59.47
-12.66%
|
68.09
|
| Working Capital |
|
11.70
+165.92%
|
4.40
-89.35%
|
41.32
-13.34%
|
47.69
|
| Invested Capital |
|
26.90
+16.97%
|
23.00
-62.31%
|
61.01
-13.88%
|
70.84
|
| Total Debt |
|
15.04
+29.76%
|
11.59
-5.95%
|
12.32
+164.98%
|
4.65
|
| Net Debt |
|
3.00
-45.61%
|
5.52
|
—
|
—
|
| Capital Lease Obligations |
|
1.60
-11.83%
|
1.82
-15.68%
|
2.16
+13.83%
|
1.89
|
| Net Tangible Assets |
|
3.01
+284.67%
|
-1.63
-105.63%
|
28.96
-37.57%
|
46.38
|
| Tangible Book Value |
|
3.01
+284.67%
|
-1.63
-105.63%
|
28.96
-37.57%
|
46.38
|
| Derivative Product Liabilities |
|
—
|
11.93
+164.63%
|
4.51
+142.55%
|
1.86
|
| Other Equity Interest |
|
5.37
+281.18%
|
1.41
+0.00%
|
1.41
+44.41%
|
0.97
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-43.87
-94.06%
|
-22.61
+13.84%
|
-26.24
-11.31%
|
-23.57
|
| Cash Flow From Continuing Operating Activities |
|
-43.87
-94.06%
|
-22.61
+13.84%
|
-26.24
-11.31%
|
-23.57
|
| Net Income From Continuing Operations |
|
-9.22
+84.79%
|
-60.61
-142.93%
|
-24.95
+7.77%
|
-27.05
|
| Depreciation Amortization Depletion |
|
4.07
+193.71%
|
1.38
+111.62%
|
0.65
-6.97%
|
0.70
|
| Depreciation And Amortization |
|
4.07
+193.71%
|
1.38
+111.62%
|
0.65
-6.97%
|
0.70
|
| Other Non Cash Items |
|
-0.94
-180.91%
|
1.16
+161.35%
|
0.45
+1041.03%
|
0.04
|
| Stock Based Compensation |
|
1.14
-51.10%
|
2.32
+3.39%
|
2.25
+50.17%
|
1.50
|
| Asset Impairment Charge |
|
1.26
-81.26%
|
6.70
|
0.00
|
0.00
|
| Operating Gains Losses |
|
-18.35
-263.31%
|
11.24
+291.38%
|
-5.87
-429.09%
|
1.78
|
| Gain Loss On Investment Securities |
|
-18.30
-265.51%
|
11.05
+276.75%
|
-6.25
-423.04%
|
1.94
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.05
-129.12%
|
0.18
-52.48%
|
0.38
+351.97%
|
-0.15
|
| Change In Working Capital |
|
-21.82
-243.55%
|
15.20
+1127.71%
|
1.24
+329.26%
|
-0.54
|
| Change In Receivables |
|
-2.12
-491.62%
|
-0.36
|
0.00
|
0.00
|
| Changes In Account Receivables |
|
-2.12
-491.62%
|
-0.36
|
0.00
|
0.00
|
| Change In Inventory |
|
-1.19
+38.97%
|
-1.95
|
0.00
|
0.00
|
| Change In Prepaid Assets |
|
-0.04
+95.52%
|
-0.96
-47.54%
|
-0.65
-2808.33%
|
0.02
|
| Change In Payables And Accrued Expense |
|
-5.51
-199.93%
|
5.51
+191.95%
|
1.89
+434.75%
|
-0.56
|
| Change In Other Working Capital |
|
-12.96
-200.00%
|
12.96
|
—
|
—
|
| Investing Cash Flow |
|
29.37
+1934.21%
|
1.44
-63.95%
|
4.01
+110.48%
|
-38.22
|
| Cash Flow From Continuing Investing Activities |
|
29.37
+1934.21%
|
1.44
-63.95%
|
4.01
+110.48%
|
-38.22
|
| Net PPE Purchase And Sale |
|
-0.05
+54.31%
|
-0.12
+11.45%
|
-0.13
-35.05%
|
-0.10
|
| Purchase Of PPE |
|
-0.05
+54.31%
|
-0.12
+11.45%
|
-0.13
-35.05%
|
-0.10
|
| Capital Expenditure |
|
-0.05
+81.82%
|
-0.30
+6.01%
|
-0.32
-225.77%
|
-0.10
|
| Net Investment Purchase And Sale |
|
29.43
+1590.29%
|
1.74
-59.72%
|
4.32
+111.34%
|
-38.13
|
| Purchase Of Investment |
|
-26.35
+44.63%
|
-47.59
-8.15%
|
-44.00
+43.59%
|
-78.00
|
| Sale Of Investment |
|
55.78
+13.07%
|
49.33
+2.08%
|
48.32
+21.19%
|
39.87
|
| Net Intangibles Purchase And Sale |
|
-0.00
+99.45%
|
-0.18
+2.16%
|
-0.18
|
0.00
|
| Purchase Of Intangibles |
|
-0.00
+99.45%
|
-0.18
+2.16%
|
-0.18
|
0.00
|
| Financing Cash Flow |
|
20.66
+37.21%
|
15.06
-26.33%
|
20.44
-64.61%
|
57.75
|
| Cash Flow From Continuing Financing Activities |
|
20.66
+37.21%
|
15.06
-26.33%
|
20.44
-64.61%
|
57.75
|
| Net Issuance Payments Of Debt |
|
4.28
+315.24%
|
-1.99
-132.73%
|
6.07
+270.04%
|
-3.57
|
| Issuance Of Debt |
|
19.22
|
0.00
-100.00%
|
9.13
|
0.00
|
| Repayment Of Debt |
|
-14.94
-651.71%
|
-1.99
+34.86%
|
-3.05
+14.56%
|
-3.57
|
| Long Term Debt Issuance |
|
19.22
|
0.00
-100.00%
|
9.13
|
0.00
|
| Long Term Debt Payments |
|
-14.94
-651.71%
|
-1.99
+34.86%
|
-3.05
+14.56%
|
-3.57
|
| Net Long Term Debt Issuance |
|
4.28
+315.24%
|
-1.99
-132.73%
|
6.07
+270.04%
|
-3.57
|
| Net Common Stock Issuance |
|
16.36
+16.10%
|
14.09
-1.88%
|
14.36
-71.51%
|
50.41
|
| Proceeds From Stock Option Exercised |
|
0.02
-99.26%
|
2.96
+59000.00%
|
0.01
-99.95%
|
10.91
|
| Changes In Cash |
|
6.16
+200.83%
|
-6.11
-240.09%
|
-1.80
+55.63%
|
-4.05
|
| Effect Of Exchange Rate Changes |
|
0.02
+109.82%
|
-0.22
+63.10%
|
-0.61
-393.24%
|
0.21
|
| Beginning Cash Position |
|
4.25
-59.81%
|
10.59
-18.50%
|
12.99
-22.82%
|
16.83
|
| End Cash Position |
|
10.44
+145.26%
|
4.25
-59.81%
|
10.59
-18.50%
|
12.99
|
| Free Cash Flow |
|
-43.93
-91.78%
|
-22.91
+13.75%
|
-26.56
-12.19%
|
-23.67
|
| Interest Paid Supplemental Data |
|
10.39
+834.92%
|
1.11
+87.35%
|
0.59
-13.05%
|
0.68
|
| Common Stock Issuance |
|
16.36
+16.10%
|
14.09
-1.88%
|
14.36
-71.51%
|
50.41
|
| Issuance Of Capital Stock |
|
16.36
+16.10%
|
14.09
-1.88%
|
14.36
-71.51%
|
50.41
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|